DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead

DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead

Source: 
Xconomy
snippet: 

DBV Technologies is jumping back into the race to bring an FDA-approved peanut allergy treatment to the market, but it might not be enough to beat its main rival.